S'abonner

Do serum biomarkers correlate to the risk of gastric lesions in patients with autoimmune gastritis༟—A systematic review and meta-analysis - 04/11/25

Doi : 10.1016/j.clinre.2025.102722 
Zijin Liu a, 1 , Yingqi Wang a, 1 , Jiayi Hong a , Fang He a , Lijie Hao a , Linmin Liu b , Huihong Zhai a,
a Department of Gastroenterology and Hepatology, National Clinical Research Center for Geriatric Diseases, Xuanwu Hospital, Capital Medical University, Beijing 100053, China 
b Department of Gastroenterology and Hepatology, Xiongan Xuanwu Hospital, Capital Medical University, Hebei 071702, China 

Corresponding author at: Department of Gastroenterology and Hepatology, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.Department of Gastroenterology and HepatologyXuanwu Hospital, Capital Medical UniversityBeijing100053China

Highlights

This article proved that serum gastrin levels are significantly elevated in AIG patients with gastric neuroendocrine tumors (NETs) or gastric polyps (GPs). A clear correlation was found, with weighted mean gastrin levels of 811.53 pg/mL indicating increased risk for NETs and 240.02 pg/mL for GPs.
Besides, other serum biomarkers (chromogranin A, vitamin B12, parietal cell antibody) show inconsistent associations with NET or GP development.None provided reliable predictive value, highlighting the specificity of gastrin in this context.
What’s more, limited data suggest a milder gastrin elevation but higher H. pylori co-infection rate in AIG patients with gastric cancer. Older male patients with hypergastrinemia or H. pylori infection may warrant enhanced vigilance for gastric adenocarcinoma.
Last but not least, this study provides evidence-based guidance for endoscopic monitoring in AIG, addressing a significant gap in current clinical guidelines. Individualized screening intervals based on gastrin levels could improve early detection of neoplastic lesions.

Le texte complet de cet article est disponible en PDF.

Abstract

Background & Aims

Current surveillance strategies for autoimmune gastritis (AIG) lack consensus, and the prognostic role of serum biomarkers remains unclear. This meta-analysis aimed to evaluate the correlation between serum biomarkers and the risks of gastric lesions in AIG patients.

Methods

Studies comparing serum biomarkers in AIG patients with versus without neuroendocrine tumor (NET), gastric polyp (GP), or gastric cancer (GC) were identified by searching PubMed, EMBASE, and Cochrane databases (up to March 2025). Basic studies, meta-analyses, reviews, case reports, or studies not published in English were excluded. Two investigators independently extracted data and quality-assessed using the Newcastle–Ottawa and AHRQ scales. Statistical analysis used Review Manager 5.4 and Stata MP18. Heterogeneity and publication bias were evaluated. Sensitivity analysis was used to manage heterogeneity and assess the stability of the result.

Results

Thirteen studies (10 for NET, 4 for GP, and 1 for GC) were included. Elevated serum gastrin correlated significantly with NET (MD: 519.05, 95% CI: 227.96∼810.13, P = 0.0005, I2=85%) and GP (MD: 70.54, 95% CI: 43.59∼97.49, P < 0.00001, I2=0%; weighted mean: 240.02 pg/ml). With a high heterogeneity in the NET group, we arranged sensitivity analysis and removed two studies that caused heterogeneity, the result consistently showed a statistical difference (MD: 196.62, 95% CI: 76.61∼316.64, P = 0.001, I2=22%; weighted mean: 811.53 pg/ml). Publication bias was found neither in NET (Begg’s test: P = 0.1078, Egger’s test: P = 0.3553) nor in GP (Begg’s test: P = 1.0000, Egger’s test: P = 0.4771) groups. Chromogranin A (CgA), vitamin B12, and parietal cell antibody (PCA) showed no consistent associations. For GC, limited data suggested milder gastrin elevation and higher Helicobacter pylori co-infection rates.

Discussion

Serum gastrin is correlated with NET and GP in AIG patients. The weighted mean serum gastrin level was 811.53 pg/ml in AIG patients with NET, and 240.02 pg/ml in those with GP. Non-enrollment of randomized controlled trials (RCTs), inconsistency in laboratory methods for biomarker detection and diagnostic criteria, and different units of biomarkers may cause limitations of the present study.

Le texte complet de cet article est disponible en PDF.

Key words : Autoimmune gastritis, Gastrin, Gastric neuroendocrine tumor, Gastric polyp, Gastric cancer


Plan


© 2025  Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 49 - N° 10

Article 102722- décembre 2025 Retour au numéro
Article précédent Article précédent
  • Cirrhotic cardiomyopathy in children: A comprehensive assessment using ECG, echocardiography, and NT-Pro-BNP
  • Ataollahi Maryam, Naghshzan Amir, Haghighat Mahmood, Dehghani Mohsen, Amuzgar Hamid, Kalvandi Gholamreza, Mehdizadegan Nima, Salarian Leila
| Article suivant Article suivant
  • Gastrointestinal stromal tumor presenting in the pancreas
  • Jia-Lu Long, Peng Liu

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.